Korean Collection for Type Cultures, Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.
Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Microbiol Spectr. 2022 Dec 21;10(6):e0253122. doi: 10.1128/spectrum.02531-22. Epub 2022 Nov 30.
The gut microbiota (GM) is associated with colorectal cancer (CRC) development. However, studies demonstrating the role of GM in CRC are limited to metagenomic analyses. These studies lack direct evidence proving that the candidate strains are involved in CRC, and isolated probiotics for bacteriotherapy. Therefore, to identify novel GM with anti-CRC activity, we previously isolated gut bacteria from the feces of healthy individuals, screened the isolated GM's anti-CRC activity, and discovered that cell-free supernatants of GM isolates demonstrated antiproliferative activity against CRC cells. Here, our study identified one of them as Eubacterium callanderi and chose it for further study because the genus has been suggested to contribute to various aspects of gut health; however, the functions are unknown. First, we confirmed that cell-free supernatant (EcCFS) exerted antiproliferative activity-by inducing apoptosis and cell cycle arrest-that was dose-dependent and specific to cancer cell lines. Next, we discovered that EcCFS active molecules were heat stable and protease insensitive. High-performance liquid chromatography analysis revealed that EcCFS contained high butyrate concentrations possessing anticancer activity. Additionally, gas chromatography-mass spectrometry analysis of the aqueous phase of ethyl acetate-extracted EcCFS and an antiproliferation assay of the aqueous phase and 4-aminobutanoic acid (GABA) suggested that GABA is a possible anti-CRC agent. Finally, in the CT26 allograft mouse model, oral administration and EcCFS peri-tumoral injection inhibited tumor growth . Therefore, our study reveals that has an anti-CRC effect and suggests that it may be a potential candidate for developing probiotics to control CRC. The gut microbiota has been reported to be involved in colorectal cancer, as suggested by metagenomic analysis. However, metagenomic analysis has limitations, such as bias in the analysis and the absence of bacterial resources for follow-up studies. Therefore, we attempted to discover gut microorganisms that are related to colorectal cancer using the culturomics method. In this study, we discovered that Eubacterium callanderi possesses anti-colorectal cancer activity and , suggesting that could be used in bacteriotherapy for colorectal cancer treatment.
肠道微生物群(GM)与结直肠癌(CRC)的发展有关。然而,证明 GM 在 CRC 中作用的研究仅限于宏基因组分析。这些研究缺乏直接证据证明候选菌株与 CRC 有关,也缺乏用于细菌治疗的分离益生菌。因此,为了鉴定具有抗 CRC 活性的新型 GM,我们之前从健康个体的粪便中分离肠道细菌,筛选分离的 GM 的抗 CRC 活性,发现 GM 分离株的无细胞上清液对 CRC 细胞具有抗增殖活性。在这里,我们的研究鉴定出其中一种为 Eubacterium callanderi,并选择它进行进一步研究,因为该属被认为有助于肠道健康的各个方面;但是,其功能尚不清楚。首先,我们证实无细胞上清液(EcCFS)通过诱导细胞凋亡和细胞周期停滞发挥抗增殖作用,且该作用呈剂量依赖性和对癌细胞系特异性。接下来,我们发现 EcCFS 活性分子耐热且对蛋白酶不敏感。高效液相色谱分析显示,EcCFS 含有高浓度但具有抗癌活性的丁酸。此外,对乙酸乙酯提取的 EcCFS 水相的气相色谱-质谱分析和水相和 4-氨基丁酸(GABA)的增殖抑制试验表明,GABA 可能是一种潜在的抗 CRC 剂。最后,在 CT26 同种异体移植小鼠模型中,口服和 EcCFS 肿瘤周围注射抑制肿瘤生长。因此,我们的研究表明 Eubacterium callanderi 具有抗 CRC 作用,并表明它可能是开发用于控制 CRC 的益生菌的潜在候选物。肠道微生物群已被报道与结直肠癌有关,这是宏基因组分析的结果。然而,宏基因组分析存在局限性,例如分析中的偏差和缺乏后续研究的细菌资源。因此,我们尝试使用培养组学方法发现与结直肠癌相关的肠道微生物。在这项研究中,我们发现 Eubacterium callanderi 具有抗结直肠癌活性,这表明它可以用于结直肠癌的细菌治疗。